Long-term real-world outcomes of first-line immunotherapy in non-small cell lung cancer – a population-based cohort study in Sweden
DOI:
https://doi.org/10.2340/1651-226X.2025.42746Keywords:
combination therapy, immune checkpoint inhibitor, monotherapy, overall survival, PD-L1Abstract
Background: In a previous study, we explored real-world programmed death-ligand 1 (PD-L1) testing and treatment patterns for patients with advanced non-small cell lung cancer (NSCLC) in the era of immune-oncology. The present study aimed to investigate overall survival (OS) with PD-(L)1 inhibitors with longer-term follow-up in the Swedish setting.
Materials and methods: Data were extracted from the Swedish National Lung Cancer Registry for patients with NSCLC stage IIIB-IV and ECOG performance status (PS) 0–2 who initiated first-line systemic treatment from 1-April-2017 to 30-June-2021 with data cut-off 30-June-2022. OS and Kaplan–Meier estimates were calculated from start of the PD-(L)1 inhibitor therapy, with subgroups based on nonsquamous/squamous (NSQ/SQ) histology, and further by PS, and PD-L1 status (available from 1-January-2018) provided sufficient sample size.
Results: We identified 784 (NSQ:590/SQ:194) patients treated with first-line PD-(L)1 inhibitor monotherapy and 369 (NSQ:305/SQ:64) patients receiving combination regimens. Median OS (95% confidence interval [CI]) was 15.2 (12.4–17.7) and 12.9 (10.6–15.8) months with monotherapy and 17.0 (13.6–23.9) and 18.0 (13.9-NA) months with combination regimens for NSQ/SQ patients. In PS2, median OS with monotherapy was 5.0 (3.7–7.1) and 8.9 (6.2–12.9) months for NSQ/SQ patients (n = 138/59), 5.3 (3.6–13.4) months with combination regimens in NSQ (n = 58) and not evaluable in SQ patients. For PS0-1 patients with tumor cell PD-L1 expression ≥50%, the median OS for NSQ was 23.8 (17.7–29.3) and 27.3 (21.6-NA) months for monotherapy/combination therapy (n = 281/55), while the median OS for combination regimens for PD-L1 <1% and 1–49% was 18.6 (12.1–26.9) and 15.9 (10.8–26.7) months (NSQ; n = 65/87).
Interpretation: Real-world OS in Swedish patients receiving first-line PD-(L)1 inhibitor-based regimens was consistent with that observed in clinical trials. Moderate OS rates were observed in PS2, with limited sample sizes. Further research is needed in these patients, as well as in high PD-L1, given the slightly longer OS for combination therapy compared to monotherapy seen for NSQ.
Downloads
References
World Health Organization. WHO fact sheet. Cancer. [cited 2024 Jun 22]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer
Socialstyrelsen. Cancer i siffror – Populärvetenskapliga fakta om cancer. 2023 [cited 2024 Jun 22]. Available from: https://www.socialstyrelsen.se/statistik-och-data/statistik/alla-statistikamnen/cancer/ [in Swedish].
Ganti AK, Klein AB, Cotarla I, Seal B, Chou E. Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US. JAMA Oncol. 2021;7:1824–32.
https://doi.org/10.1001/jamaoncol.2021.4932 DOI: https://doi.org/10.1001/jamaoncol.2021.4932
The WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon, France: IARC Press; 2021.
Wagenius G, Vikström A, Berglund A, Salomonsson S, Bencina G, Hu X, et al. First-line treatment patterns and outcomes in advanced non-small cell lung cancer in Sweden: a population-based real-world study with focus on immunotherapy. Acta Oncol. 2024;63:198–205.
https://doi.org/10.2340/1651-226X.2024.20309 DOI: https://doi.org/10.2340/1651-226X.2024.20309
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39:2339–49.
https://doi.org/10.1200/JCO.21.00174 DOI: https://doi.org/10.1200/JCO.21.00174
de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 Study. J Clin Oncol. 2023;41:1986–91.
https://doi.org/10.1200/JCO.21.02885 DOI: https://doi.org/10.1200/JCO.21.02885
Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol. 2020;38:1505–17.
https://doi.org/10.1200/JCO.19.03136 DOI: https://doi.org/10.1200/JCO.19.03136
Socinski MA, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J Thorac Oncol. 2021;16:1909–24.
https://doi.org/10.1016/j.jtho.2021.07.009 DOI: https://doi.org/10.1016/j.jtho.2021.07.009
Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41:1999–2006.
https://doi.org/10.1200/JCO.22.01990 DOI: https://doi.org/10.1200/JCO.22.01990
Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J Thorac Oncol. 2020;15:1351–60.
https://doi.org/10.1016/j.jtho.2020.03.028 DOI: https://doi.org/10.1016/j.jtho.2020.03.028
Verschueren MV, Peters BJ, Bloem LT, Kruik VR, Uitvlugt EB, Bijsmans AR, et al. Pembrolizumab plus chemotherapy per PD-L1 stratum in patients with metastatic non-small cell lung cancer: real-world effectiveness versus trial efficacy. Clin Lung Cancer. 2024;25:119–27.e1.
https://doi.org/10.1016/j.cllc.2023.12.011 DOI: https://doi.org/10.1016/j.cllc.2023.12.011
Waterhouse D, Lam J, Betts KA, Yin L, Gao S, Yuan Y, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. Lung Cancer. 2021;156:41–9.
https://doi.org/10.1016/j.lungcan.2021.04.007 DOI: https://doi.org/10.1016/j.lungcan.2021.04.007
Liu SV, Hu X, Li Y, Zhao B, Burke T, Velcheti V. Pembrolizumab combination therapy for previously untreated metastatic nonsquamous NSCLC: real-world outcomes at US oncology practices. Front Oncol. 2022;12:999343.
https://doi.org/10.3389/fonc.2022.999343 DOI: https://doi.org/10.3389/fonc.2022.999343
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, et al. Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed. Eur J Cancer. 2024;202:114006. DOI: https://doi.org/10.1016/j.ejca.2024.115057
https://doi.org/10.1016/j.ejca.2024.114006 DOI: https://doi.org/10.1016/j.ejca.2024.114006
Di Federico A, De Giglio A, Parisi C, Gelsomino F, Ardizzoni A. PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: selecting the best strategy. Crit Rev Oncol Hematol. 2021;160:103302.
https://doi.org/10.1016/j.critrevonc.2021.103302 DOI: https://doi.org/10.1016/j.critrevonc.2021.103302
Dudnik E, Moskovitz M, Rottenberg Y, Lobachov A, Mandelboim R, Shochat T, et al. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data. Oncoimmunology. 2021;10:1865653.
https://doi.org/10.1080/2162402X.2020.1865653 DOI: https://doi.org/10.1080/2162402X.2020.1865653
Regionala Cancercentrum i Samverkan. Nationellt Vårdprogram lungcancer. [cited 2025 Feb 05]. Available from: https://kunskapsbanken.cancercentrum.se/diagnoser/lungcancer/vardprogram/ [in Swedish].
Middleton G, Brock K, Savage J, Mant R, Summers Y, Connibear J, et al. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med. 2020;8:895–904.
https://doi.org/10.1016/S2213-2600(20)30033-3 DOI: https://doi.org/10.1016/S2213-2600(20)30033-3
Veluswamy R, Hu L, Smith C, Ji J, Wang X, Wisnivesky J, et al. Immunotherapy outcomes in individuals with non-small cell lung cancer and poor performance status. JNCI Cancer Spectr. 2022;6:pkac013.
https://doi.org/10.1093/jncics/pkac013 DOI: https://doi.org/10.1093/jncics/pkac013
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, et al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020;130:155–67.
https://doi.org/10.1016/j.ejca.2020.02.023 DOI: https://doi.org/10.1016/j.ejca.2020.02.023
Ahmed T, Lycan T, Dothard A, Ehrlichman P, Ruiz J, Farris M, et al. Performance status and age as predictors of immunotherapy outcomes in advanced non-small-cell lung cancer. Clin Lung Cancer. 2020;21:e286–93.
https://doi.org/10.1016/j.cllc.2020.01.001 DOI: https://doi.org/10.1016/j.cllc.2020.01.001
Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, et al. Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors. JTO Clin Res Rep. 2023;4:100482.
https://doi.org/10.1016/j.jtocrr.2023.100482 DOI: https://doi.org/10.1016/j.jtocrr.2023.100482
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gunnar Wagenius, Anders Vikström, Anders Berglund, Stina Salomonsson, Goran Bencina, Xiaohan Hu, Diana Chirovsky, Hans Brunnström
This work is licensed under a Creative Commons Attribution 4.0 International License.
